(Q30395200)

10 October 2017

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host (English)

1 reference

10 October 2017

Hugues de Lavallade

1

1 reference

10 October 2017

Paula Garland

2

1 reference

10 October 2017

Takuya Sekine

3

1 reference

10 October 2017

Katja Hoschler

4

1 reference

10 October 2017

David Marin

5

1 reference

10 October 2017

Kate Stringaris

6

1 reference

10 October 2017

Eva Loucaides

7

1 reference

10 October 2017

Katherine Howe

8

1 reference

10 October 2017

Richard Szydlo

9

1 reference

10 October 2017

Ed Kanfer

10

1 reference

10 October 2017

Donald Macdonald

11

1 reference

10 October 2017

Peter Kelleher

12

1 reference

10 October 2017

Nichola Cooper

13

1 reference

10 October 2017

Ahmad Khoder

14

1 reference

10 October 2017

Ian H Gabriel

15

1 reference

10 October 2017

Dragana Milojkovic

16

1 reference

10 October 2017

Jiri Pavlu

17

1 reference

10 October 2017

John M Goldman

18

1 reference

10 October 2017

Jane F Apperley

19

1 reference

10 October 2017

Katayoun Rezvani

20

1 reference

10 October 2017

22 October 2010

1 reference

10 October 2017

1 reference

10 October 2017

96

1 reference

10 October 2017

2

1 reference

10 October 2017

307-314

1 reference

Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation

10 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Clinical and immunologic predictors of influenza illness among vaccinated older adults

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Utility of influenza vaccination for oncology patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Response to a monovalent 2009 influenza A (H1N1) vaccine.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Influenza vaccination in hematopoietic SCT recipients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Influenza vaccination and chemotherapy: a shot in the dark?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Response to influenza virus vaccine in children receiving chemotherapy for malignancy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Rituximab treatment results in impaired secondary humoral immune responsiveness.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031700

26 November 2018

1 reference

12 December 2020

Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy

1 reference

12 December 2020

Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study

1 reference

12 December 2020

T cell responses are better correlates of vaccine protection in the elderly

1 reference

12 December 2020

10.3324/HAEMATOL.2010.032664

Identifiers

DOI

1 reference

10 October 2017

1 reference

10 October 2017

1 reference